Galmed Pharmaceuticals
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- $1.8M
- Website
- http://galmedpharma.com
- Introduction
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese ...
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Aramchol 300mg BID shows significant anti-fibrotic effects in MASH patients, confirmed by NASH CRN, paired ranked reading, and AI digital analysis. Published in Hepatology, the study highlights Aramchol's potential as a therapeutic option for MASH and fibrosis.
Galmed Announces an Expansion of its Activities to Cancer and Major Cardiometabolic Diseases
Galmed Pharmaceuticals plans to expand drug development activities, focusing on novel Aramchol-based combinations for advanced colorectal and hepatic cancers, and cardiac fibrosis. The expansion is driven by recent scientific publications highlighting SCD1 inhibition's potential in cardiometabolic diseases, cancer, and neuroprotection.
© Copyright 2024. All Rights Reserved by MedPath